2026: Neuroblastoma Pre-Infusion

The Neuroblastoma Pre-HCT Data Form (Form 2026) is one of the Comprehensive Report Forms. This form captures neuroblastoma specific pre-HCT data such as: the recipient’s clinical and laboratory findings at the time of diagnosis and prior to the start of the preparative regimen, pre-HCT treatments administered, and disease manifestations prior to the preparative regimen.

This form must be completed for all recipients randomized to the Comprehensive Report Form (CRF) track whose primary disease is reported on the Pre-TED Disease Classification Form (Form 2402) as Neuroblastoma under “Solid tumors.”

*MIBG Therapy and Additional Infusion of Cells
MIBG therapy has been used to deliver targeted radiation to patients with neuroblastoma. This therapy destroys tumors while sparing normal, healthy tissue. MIBG therapy is currently may be used to treat newly diagnosed, used to treat relapsed or refractory neuroblastoma and is being studied as treatment for newly diagnosed high risk patients.
Treatment for high-risk neuroblastoma includes the following:
Induction therapy: Chemotherapy, stem cell collection, surgical resection of primary tumor
Consolidation therapy: High-dose chemotherapy followed by Autologous HCT, radiation therapy
Maintenance therapy: Immunotherapy, Cis-Retinoic acid
Clinical trials have randomized newly diagnosed high risk neuroblastoma patients with MIBG-avid disease to either standard induction therapy or standard induction therapy with the addition of I-131 MIBG. Since the most common side effect of MIBG therapy is low blood counts, the patient’s hematopoietic progenitor stem cells (HPCs or CD34+ cells) are collected and stored prior to the first treatment with MIBG. These HPCs are then available for HCT or as a “rescue” following MIBG therapy.
Effective November 2020, if a neuroblastoma recipient undergoing induction therapy with MIBG therapy receives an infusion of HPCs / CD34+ cells as a “rescue” due to low blood counts, centers no longer need to report this as an HCT.

Subsequent Transplant

If this is a report of a second or subsequent transplant for the same disease subtype, and this baseline disease insert has not been completed for the previous transplant (e.g., patient was on TED track for the prior HCT, prior HCT was autologous with no consent, etc.), begin at question 1. If this is a report of a second or subsequent transplant for a different disease (e.g., patient was previously transplanted for a disease other than neuroblastoma), begin at question 1.

If this is a report of a second or subsequent transplant for the same disease and this baseline disease insert has previously been completed, check the indicator box and continue with question 218.

Links to Sections of Form
Q1 – 61: Clinical and Laboratory Characteristics at Diagnosis
Q62 – 232: Laboratory Values at Diagnosis of Neuroblastoma
Q233 – 271: Disease Status Immediately Prior to Preparative Regimen

Manual Updates
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, please reference the retired manual section on the Retired Forms Manuals webpage.

Date	Manual Section	Add/Remove/Modify	Description
4/21/2023	2026: Neuroblastoma Pre-Infusion	Modify	Clarified the instructions for the labs at diagnosis should reflect the labs closest to the date of diagnosis in Q62.
1/25/2021	2026: Neuroblastoma Pre-Infusion	Add	Version 1 of the Neuroblastoma Pre-Infusion section of the Forms Instruction Manual released. Version 1 corresponds to revision 2 of the Form 2026.

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.